Skip to main content
. Author manuscript; available in PMC: 2012 Jan 21.
Published in final edited form as: Oncogene. 2011 Mar 21;30(29):3207–3221. doi: 10.1038/onc.2011.35

Figure 1. Doxorubicin and Nutlin elicit an increase in FoxO3 protein expression that is p53-dependent in MEFs.

Figure 1

(A) Western-blot of protein extracts from p53+/+ and p53−/− MEFs incubated in the absence (−) or presence (+) of doxorubicin (Dox, 0.2 μg/ml) for 8 hours, using antibodies to FoxO3, p21Cip1 (a well-known target of p53), p53, and Mek1 (loading control). (B) Western-blot of protein extracts from p53+/+ and p53−/− MEFs incubated with Nutlin (10 μM), a p53 activator, or Doxorubicin (Dox, 0.2 μg/ml) for 0, 4, and 8 hours, using antibodies to FoxO3, p53, and β-actin (loading control). Western-blots are representative of at least two independent experiments, conducted on independent cultures of MEFs.